BlackRock’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,748,077
| Closed | -$12.4M | – | 5622 |
|
|
2025
Q2 | $12.4M | Sell |
2,748,077
-153,948
| -5% | -$692K | ﹤0.01% | 3302 |
|
|
2025
Q1 | $12.9M | Sell |
2,902,025
-96,447
| -3% | -$560K | ﹤0.01% | 3189 |
|
|
2024
Q4 | $23.5M | Sell |
2,998,472
-26,763
| -0.9% | -$326K | ﹤0.01% | 2940 |
|
|
2024
Q3 | $39.8M | Buy |
3,025,235
+86,517
| +3% | +$1.1M | ﹤0.01% | 2621 |
|
|
2024
Q2 | $35.5M | Buy |
2,938,718
+81,461
| +3% | +$1.1M | ﹤0.01% | 2620 |
|
|
2024
Q1 | $46.5M | Sell |
2,857,257
-59,823
| -2% | -$806K | ﹤0.01% | 2473 |
|
|
2023
Q4 | $19.9M | Buy |
2,917,080
+443,724
| +18% | +$2.57M | ﹤0.01% | 3017 |
|
|
2023
Q3 | $13.5M | Sell |
2,473,356
-58,423
| -2% | -$340K | ﹤0.01% | 3152 |
|
|
2023
Q2 | $17.2M | Buy |
2,531,779
+170,686
| +7% | +$1.28M | ﹤0.01% | 3127 |
|
|
2023
Q1 | $11.8M | Sell |
2,361,093
-217,683
| -8% | -$889K | ﹤0.01% | 3229 |
|
|
2022
Q4 | $12.6M | Sell |
2,578,776
-318,618
| -11% | -$2.31M | ﹤0.01% | 3284 |
|
|
2022
Q3 | $41.8M | Sell |
2,897,394
-78,827
| -3% | -$1.31M | ﹤0.01% | 2582 |
|
|
2022
Q2 | $45M | Buy |
2,976,221
+31,127
| +1% | +$363K | ﹤0.01% | 2563 |
|
|
2022
Q1 | $35M | Buy |
2,945,094
+177,734
| +6% | +$1.83M | ﹤0.01% | 2799 |
|
|
2021
Q4 | $44.9M | Buy |
2,767,360
+30,500
| +1% | +$652K | ﹤0.01% | 2727 |
|
|
2021
Q3 | $78.1M | Buy |
2,736,860
+33,169
| +1% | +$1.05M | ﹤0.01% | 2367 |
|
|
2021
Q2 | $91.4M | Buy |
2,703,691
+178,915
| +7% | +$5.74M | ﹤0.01% | 2311 |
|
|
2021
Q1 | $76.3M | Buy |
2,524,776
+106,196
| +4% | +$4.35M | ﹤0.01% | 2346 |
|
|
2020
Q4 | $120M | Buy |
2,418,580
+72,823
| +3% | +$3.37M | ﹤0.01% | 1972 |
|
|
2020
Q3 | $90.1M | Buy |
2,345,757
+33,965
| +1% | +$1.35M | ﹤0.01% | 1943 |
|
|
2020
Q2 | $99.9M | Buy |
2,311,792
+331,723
| +17% | +$12.5M | ﹤0.01% | 1846 |
|
|
2020
Q1 | $51.7M | Sell |
1,980,069
-33,022
| -2% | -$959K | ﹤0.01% | 2024 |
|
|
2019
Q4 | $62.9M | Buy |
2,013,091
+688,524
| +52% | +$20.4M | ﹤0.01% | 2219 |
|
|
2019
Q3 | $34.5M | Buy |
1,324,567
+170,736
| +15% | +$4.36M | ﹤0.01% | 2508 |
|
|
2019
Q2 | $26.4M | Buy |
1,153,831
+784,672
| +213% | +$18M | ﹤0.01% | 2689 |
|
|
2019
Q1 | $9.68M | Buy |
369,159
+27,328
| +8% | +$600K | ﹤0.01% | 3130 |
|
|
2018
Q4 | $6.95M | Buy |
341,831
+326,831
| +2,179% | +$7.51M | ﹤0.01% | 3268 |
|
|
2018
Q3 | $398K | Buy |
+15,000
| New | +$381K | ﹤0.01% | 4171 |
|
Other funds holding YMAB
BlackRock's YMAB Position: Q3 2025 in Review
BlackRock sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 2,748,077 shares — an estimated $12.4M sold.
BlackRock first reported a position in YMAB in Q3 2018 and held it in 28 quarters. The position peaked at $120M in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- BlackRock reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- BlackRock sold 2,748,077 Y-mAbs Therapeutics shares in Q3 2025, an estimated $12.4M.
- BlackRock first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 28 quarters.
- BlackRock's Y-mAbs Therapeutics position peaked at $120M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.